Dublin, March 09, 2026 (GLOBE NEWSWIRE) — The “Anticoagulants Market Companies Analysis Key Players Analysis, Company Profiles, Product Developments, Mergers, Strategic Collaborations, and Revenue Forecast Insights” has been added to ResearchAndMarkets.com’s offering.
The international market for anticoagulants was estimated at around US$ 45.02 billion in 2025. It is expected to expand at a compound annual growth rate (CAGR) of 8.97% during the period 2025-2033 and reach an estimated value of around US$ 89.50 billion in 2033.
The market for anticoagulants is expanding rapidly as a result of the increased incidence of venous thromboembolism, stroke, and cardiovascular illnesses worldwide. Major contributing factors include the expanding older population, which is more susceptible to clot-related illnesses, and growing understanding of preventive healthcare.
The market has expanded more quickly due to the use of novel oral anticoagulants (NOACs), which have better safety profiles and don’t need to be monitored as frequently as warfarin. Demand is further increased by continuous clinical research, improved access to healthcare in emerging nations, and technological developments in drug formulation. Furthermore, the market for anticoagulants is continuing to develop thanks to advantageous reimbursement policies and a rise in the diagnosis of clotting disorders.
Top Companies in Anticoagulants Industry
Alexion Pharmaceuticals Inc.
Establishment: 1992
Headquarters: United States of America
AstraZeneca Plc’s subsidiary, Alexion Pharmaceuticals Inc. (Alexion), is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for rare and severe diseases. The company’s product portfolio includes eculizumab for treating atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa for hypophosphatasia (HPP); ravulizumab-cwvz and danicopan for PNH; and sebelipase alfa for lysosomal acid lipase (LAL) deficiency.
Additionally, selumetinib is indicated for neurofibromatosis type 1 (NF1), while Alexion also develops therapies for generalized myasthenia gravis (gMG). Its key brands include SOLIRIS, ULTOMIRIS, STRENSIQ, KANUMA, KOSELUGO, and VOYDEYA. Alexion operates across North America, Europe, Latin America, Asia Pacific, and the Middle East, ensuring global access to its innovative treatments for rare diseases. The company’s headquarters are located in Boston, Massachusetts, USA.
Bristol-Myers Squibb Company
Establishment: 1887
Headquarters: United States of America
Daiichi Sankyo Company Limited
Establishment: 2005
Headquarters: Japan
GlaxoSmithKline plc
Establishment: 2000
Headquarters: United Kingdom
Sanofi
Establishment: 1973
Headquarters: France
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2025 – 2033 |
| Estimated Market Value (USD) in 2025 | $45.02 Billion |
| Forecasted Market Value (USD) by 2033 | $89.5 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
Key Topics Covered:
1. Anticoagulants Market
1.1 Historical Trends
1.2 Forecast Analysis
2. Market Share Analysis – Anticoagulants Market
3. Alexion Pharmaceuticals Inc.
3.1 Overview
3.1.1 Company History and Mission
3.1.2 Business Model and Operations
3.1.3 Workforce
3.2 Key Persons
3.2.1 Executive Leadership
3.2.2 Operational Management
3.2.3 Division Leaders
3.2.4 Board Composition
3.3 Recent Development & Strategies
3.3.1 Mergers & Acquisitions
3.3.2 Partnerships
3.3.3 Investments
3.4 Sustainability Analysis
3.4.1 Renewable Energy Adoption
3.4.2 Energy-Efficient Infrastructure
3.4.3 Use of Sustainable Packaging Materials
3.4.4 Water Usage and Conservation Strategies
3.4.5 Waste Management and Circular Economy Initiatives
3.5 Product Analysis
3.5.1 Product Profile
3.5.2 Quality Standards
3.5.3 Product Pipeline
3.5.4 Product Benchmarking
3.6 Strategic Assessment: SWOT Analysis
3.6.1 Strengths
3.6.2 Weaknesses
3.6.3 Opportunities
3.6.4 Threats
3.7 Revenue Analysis
Above Information Will Be Provided for All the Following Companies
- Aspen Holdings
- Bayer AG
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Dr. Reddy’s Laboratories Ltd
- GlaxoSmithKline plc
- Johnson & Johnson Private Limited
- Pfizer Inc.
- Sanofi
- Boehringer Ingelheim International GmbH
- Abbott Laboratories
- AstraZeneca PLC
- Merck & Co., Inc.
- Novartis International AG
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd
- Portola Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Ltd
- Lupin Limited
For more information about this report visit https://www.researchandmarkets.com/r/a95c7m
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
